FDA Grants Accelerated Approval for Tudriqev in Advanced Melanoma
The FDA has approved Tudriqev, a genetically modified oncolytic viral therapy, for treatment-resistant advanced melanoma.
Asset / Drug
Drug and asset intelligence for Tudriqev with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Oncolytic Virus Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.